TY - JOUR T1 - Effect of Low Molecular Weight Fucoidan and Low Molecular Weight Heparin in a Rabbit Model of Arterial Thrombosis A1 - Durand,E A1 - Helley,D A1 - Zen,A A1 - Dujols,C A1 - Bruneval,P A1 - Colliec-Jouault,Sylvia A1 - Fischer,Aurelie A1 - Lafont,A AD - Hop Europeen Georges Pompidou, Serv Cardiol, AP HP, FR-75908 Paris 15, France. AD - Univ Paris 05, Fac Med, Paris, France. AD - INSERM, U849, Paris, France. AD - INSERM, U765, Paris, France. AD - INSERM, U430, Paris, France. AD - IFREMER, Lab Biotechnol & Mol Marines, Nantes, France. UR - https://archimer.ifremer.fr/doc/00000/4744/ DO - 10.1159/000129687 KW - Tissue factor KW - Tissue factor pathway inhibitor KW - Heparin KW - Fucoidan KW - Thrombosis N2 - Background: Therapeutic use of unfractionated heparin and low molecular weight heparins (LMWHs) is limited by hemorrhagic adverse effects. We compared the antithrombotic effect of LMW fucoidan (LMWF) and LMWH in an experimental model. Methods: Thrombosis was induced in femoral arteries of male New Zealand White rabbits by in situ induction of endothelial apoptosis with staurosporine (10(-5) M for 30 min). Starting the day before apoptosis induction, the animals received subcutaneous LMWF (15 mg/kg), LMWH (enoxaparin 2.5 mg/kg) or saline solution (control group) twice a day for 4 days. Results: The degrees of apoptosis and endothelial denudation were similar in the 3 groups. The thrombotic score was significantly lower in the LMWF group than in the LMWH and control groups (p = 0.01). Tissue factor expression was significantly lower in the LMWF group than in the control and LMWH groups (p = 0.01). The plasma concentration of tissue factor pathway inhibitor was significantly increased after LMWF injection (137 +/- 28 vs. 102 +/- 17; p = 0.01), whereas no change was observed after LMWH treatment. LMWF did not prolong the bleeding time or decrease platelet aggregation. Conclusions: LMWF appeared to be more effective than LMWH for preventing arterial thrombosis in this experimental model. LMWF also had a lower hemorrhagic risk than LMWH. Copyright (C) 2008 S. Karger AG, Basel. Y1 - 2008/05 PB - Karger JF - Journal of Vascular Research SN - 1018-1172 VL - 45 IS - 6 SP - 529 EP - 537 ID - 4744 ER -